{{Infobox
| title = Nilotinib (Tasigna) for Parkinson's Disease
| image =
| label1 = Drug Name
| data1 = Nilotinib (Tasigna)
| label2 = Category
| data2 = Tyrosine Kinase Inhibitor (Repurposed)
| label3 = Target
| data3 = BCR-Abl, c-Abl
| label4 = Route
| data4 = Oral
| label5 = Manufacturer
| data5 = Novartis
| label6 = ClinicalTrials.gov
| data6 = NCT03205488, NCT05742913
}}
Nilotinib (brand name Tasigna) is a BCR-Abl tyrosine kinase inhibitor originally developed for chronic myeloid leukemia (CML) that has been repurposed for Parkinson's disease based on its ability to inhibit c-Abl (Abelson tyrosine kinase). This kinase is hyperactivated in dopaminergic neurons in PD brains and promotes alpha-synuclein aggregation, mitochondrial dysfunction, and neuronal death. The repurposing of nilotinib represents an innovative approach to targeting disease-modifying mechanisms in Parkinson's disease rather than just symptomatic relief.
Nilotinib works through multiple mechanisms relevant to Parkinson's disease pathophysiology:
Nilotinib potently inhibits c-Abl tyrosine kinase, which is hyperactivated in PD brains. c-Abl phosphorylates several key substrates:
By inhibiting c-Abl, nilotinib promotes autophagy-mediated clearance of toxic proteins:
c-Abl inhibition protects mitochondria from stress-induced damage:
| Parameter | Details |
|---|---|
| Sponsor | Georgetown University |
| Design | Randomized, double-blind, placebo-controlled |
| Duration | 12 months |
| Sample Size | 75 patients |
| Doses | 150mg, 300mg daily vs. placebo |
| Primary Endpoints | Safety, tolerability |
| Secondary Endpoints | Motor scores (MDS-UPDRS), CSF biomarkers |
Results (Pagan et al., J Parkinsons Dis 2020):
In PD trials, nilotinib is used at much lower doses than for CML:
| Condition | Dose | Frequency |
|---|---|---|
| CML (approved) | 400-600mg | Twice daily |
| PD (trial dose) | 150-300mg | Once daily |
The lower dose is used to achieve CNS penetration while minimizing side effects. Pharmacokinetic studies suggest that 150-300mg achieves adequate brain concentrations for c-Abl inhibition.
| Drug | Primary Target | CNS Penetration | Status in PD |
|---|---|---|---|
| Nilotinib | BCR-Abl/c-Abl | Good | Phase II |
| Dasatinib | Multi-kinase (Src family) | Moderate | Preclinical |
| Bosutinib | BCR-Abl/Src | Moderate | Phase I |
| Radotinib | BCR-Abl | Limited | Preclinical |
Potential biomarkers to predict treatment response:
| Biomarker | Purpose | Status |
|---|---|---|
| CSF α-syn phosphorylation | Target engagement | Elevated in PD |
| CSF NfL | Neurodegeneration | Prognostic |
| c-Abl activity | Mechanism | Research |
| LRRK2 mutation status | Patient selection | Ongoing |
The study of Nilotinib For Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.